Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartwig Huland

Showing results (81-90 of 368) with videos related to

Pageof 37
Sort By:
The Journal of Urology|November 25, 2003
Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsiesAlexander Haese, Markus Graefen, Thomas Steuber, et al.
BJU International|March 24, 2007
A critical appraisal of logistic regression-based nomograms, artificial neural networks, classification and regression-tree models, look-up tables and risk-group stratification models for prostate cancerFelix K-H Chun, Pierre I Karakiewicz, Alberto Briganti, et al.
The Prostate|March 11, 2009
Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosisAchim Fleischmann, Thorsten Schlomm, Jens Köllermann, et al.
World Journal of Urology|March 23, 2016
Impact of surgeon-defined capsular incision during radical prostatectomy on biochemical recurrence ratesPhilipp Mandel, Su J Oh, Christoph Hagner, et al.
The Journal of Urology|March 2, 2016
Low Other Cause Mortality Rates Reflect Good Patient Selection in Patients with Prostate Cancer Treated with Radical ProstatectomyKatharina Boehm, Alessandro Larcher, Zhe Tian, et al.
Urologic Oncology|April 5, 2020
Validation of the updated eighth edition of AJCC for prostate cancer: Removal of pT2 substages - Does extent of tumor involvement matter?Raisa S Pompe, Tim Neumann, Lennart Kühnke, et al.
Scandinavian Journal of Urology and Nephrology. Supplementum|July 16, 2005
Epidemiology and statistical methods in prediction of patient outcomeDavid G Bostwick, Jan Adolfsson, Harry B Burke, et al.
Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology|December 24, 2016
Ten-year experience of robot-assisted radical prostatectomy: the road from cherry-picking to standard procedureJonas Schiffmann, Alexander Haese, Katharina Boehm, et al.
European Urology|February 18, 2019
Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic OutcomesFelix Preisser, Felix K H Chun, Raisa S Pompe, et al.
JAMA Oncology|March 13, 2025
Persistent Prostate-Specific Antigen Following Radical Prostatectomy for Prostate Cancer and Mortality RiskDerya Tilki, Ming-Hui Chen, Jing Wu, et al.
Pageof 37

Showing results (81-90 of 368) with videos related to

Sort By:
Pageof 37
The Journal of Urology|November 25, 2003
Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsiesAlexander Haese, Markus Graefen, Thomas Steuber, et al.
BJU International|March 24, 2007
A critical appraisal of logistic regression-based nomograms, artificial neural networks, classification and regression-tree models, look-up tables and risk-group stratification models for prostate cancerFelix K-H Chun, Pierre I Karakiewicz, Alberto Briganti, et al.
The Prostate|March 11, 2009
Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosisAchim Fleischmann, Thorsten Schlomm, Jens Köllermann, et al.
World Journal of Urology|March 23, 2016
Impact of surgeon-defined capsular incision during radical prostatectomy on biochemical recurrence ratesPhilipp Mandel, Su J Oh, Christoph Hagner, et al.
The Journal of Urology|March 2, 2016
Low Other Cause Mortality Rates Reflect Good Patient Selection in Patients with Prostate Cancer Treated with Radical ProstatectomyKatharina Boehm, Alessandro Larcher, Zhe Tian, et al.
Urologic Oncology|April 5, 2020
Validation of the updated eighth edition of AJCC for prostate cancer: Removal of pT2 substages - Does extent of tumor involvement matter?Raisa S Pompe, Tim Neumann, Lennart Kühnke, et al.
Scandinavian Journal of Urology and Nephrology. Supplementum|July 16, 2005
Epidemiology and statistical methods in prediction of patient outcomeDavid G Bostwick, Jan Adolfsson, Harry B Burke, et al.
Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology|December 24, 2016
Ten-year experience of robot-assisted radical prostatectomy: the road from cherry-picking to standard procedureJonas Schiffmann, Alexander Haese, Katharina Boehm, et al.
European Urology|February 18, 2019
Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic OutcomesFelix Preisser, Felix K H Chun, Raisa S Pompe, et al.
JAMA Oncology|March 13, 2025
Persistent Prostate-Specific Antigen Following Radical Prostatectomy for Prostate Cancer and Mortality RiskDerya Tilki, Ming-Hui Chen, Jing Wu, et al.
Pageof 37